Improving human immunity to malaria

August 1, 2012

The deadliest form of malaria is caused the protozoan Plasmodium falciparum. During its life-cycle in human blood, the parasite P. falciparum expresses unique proteins on the surface on infected blood cells.

Antibodies to these proteins are associated with protection from malaria, however, the identity of surface protein(s) that elicit the strongest immune response is unknown.

Dr. James Beeson and colleagues at the Walter and Eliza Hall Institute of Medical Research in Victoria, Australia have developed novel assays with transgenic P. falciparum expressing modified surface proteins, allowing the researchers to quantify to surface proteins among malaria-exposed children and adults.

They found that most of the response to the surface proteins targets a parasite protein known as PfEMP1.

Moreover, the showed that people with PfEMP1-specific antibodies had a reduced risk of malaria symptoms, whereas antibodies to other surface antigens were not associated with protective immunity.

These findings suggest antibodies against PfEMP mediate human immunity to malaria and have implications for future malaria vaccine development.

Explore further: 'Protein microarrays' may reveal new weapons against malaria

More information: Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity, Journal of Clinical Investigation, 2012.

Related Stories

'Protein microarrays' may reveal new weapons against malaria

November 1, 2011
A new research technology is revealing how humans develop immunity to malaria, and could assist programs aimed at eradicating this parasitic disease.

Recommended for you

Pneumonia vaccine under development provides 'most comprehensive coverage' to date, alleviates antimicrobial concerns

October 20, 2017
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

H7N9 influenza is both lethal and transmissible in animal model for flu

October 19, 2017
In 2013, an influenza virus that had never before been detected began circulating among poultry in China. It caused several waves of human infection and in late 2016, the number of people to become sick from the H7N9 virus ...

Flu simulations suggest pandemics more likely in spring, early summer

October 19, 2017
New statistical simulations suggest that Northern Hemisphere flu pandemics are most likely to emerge in late spring or early summer at the tail end of the normal flu season, according to a new study published in PLOS Computational ...

New insights into herpes virus could inform vaccine development

October 18, 2017
A team of scientists has discovered new insights into the mechanisms of Epstein-Barr virus (EBV) infection, as well as two antibodies that block the virus' entry into cells. The findings, published in Proceedings of the National ...

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.